Acute Myeloid Leukemia (AML)
Decitabine Followed by Idarubicin and Cytarabine for AML or MDS
Phase II Trial Examining Epigenetic Priming With Decitabine Followed by Idarubicin and Cytarabine for Patients With Relapsed or Refractory AML
Investigator: Derek L. Stirewalt, MD; Conditions: Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01607645
A Phase II Study of Subcutaneous Bortezomib as Maintenance Therapy for Patients With High-risk Acute Myeloid Leukemia in Remission
Investigator: John M. Pagel, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01465386
Study of GSK2130579A Tumor-Antigen-Specific Cancer Immunotherapeutic as Post-consolidation Therapy in Adult Patients in First Complete Remission
Investigator: Elihu Estey, MD; Conditions: WT1-positive Acute Myeloid Leukemia; Status: Ongoing--Not Recruiting; Study ID: NCT00725283
A Study of Oral Clofarabine Plus Low-dose Cytarabine in Previously Treated AML Patients at Least 60 Years of Age
Investigator: John Pagel, MD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT00839982
A Phase 1, Open-label, Multicenter Study of MDX-1338 (BMS-936564) in Subjects With Relapsed/Refractory Acute Myelogenous Leukemia
Investigator: Pamela S. Becker, MD, PhD; Conditions: Acute Myeloid Leukemia; Status: Recruiting; Study ID: NCT01120457
A Phase 1 Study of AC220 (ASP2689) as Maintenance Therapy in Subjects With Acute Myeloid Leukemia Who Have Been Treated With an Allogeneic Hematopoietic Stem Cell Transplant
Investigator: Brenda Sandmaier, MD; Conditions: Acute Myeloid Leukemia (AML); Status: Recruiting; Study ID: NCT01468467
Hematopoietic Cell Transplantation for Patients With High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) Using Radiolabeled DOTA-Biotin Pretargeted by BC8 Antibody-Streptavidin Conjugate
Investigator: John M. Pagel, MD; Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome; Status: Recruiting; Study ID: NCT00988715
Phase I/II Study of Adoptive Immunotherapy After Allogeneic HCT With Virus Specific CD8+ T Cells That Have Been Transduced to Express a WT1-specific T Cell Receptor for Patients With High Risk or Relapsed AML, MDS, or CML
Investigator: Merav Bar, MD; Conditions: Acute Myeloid Leukemia (AML); Bone Marrow and Hematopoietic Stem Cell Transplant (BMT and HSCT); Leukemia; Status: Recruiting; Study ID: NCT01640301
Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS): A Phase I/II Study
Investigator: Roland Walter, MD; Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes; Status: Recruiting; Study ID: NCT01729845
Join Us On